Osteosarcoma Maintenance Therapy With OST31-164

Summary

Up to 45 Patients aged 12 to 39 with osteosarcoma (bone cancer) that had recurred in the lungs and has recently been surgically removed will be enrolled. Patients will receive OST31-164 infusions every 3 weeks over 48 weeks and be followed after that for 3 years.

Timeline

Start

2021-10-21

Primary completion

2023-09-21

Completion

2027-10-31

Drugs

Indications